© 2005-2012 American Society of Clinical Oncology (ASCO). All rights reserved worldwide.
Cancer.Net Specialty Editor: Gastrointestinal Cancers
University of Birmingham, Edgbaston, Birmingham
Dr. Philip Johnson is Professor of Oncology Translational Research at the School of Cancer Sciences in the College of Medical and Dental Sciences. Dr. Johnson's expertise is in cancer biomarkers, clinical trials, proteomics, and liver cancer. Dr. Johnson obtained his medical degree from the University of Manchester and completed his training at several leading medical institutions in London.
Dr. Johnson led one of the largest cancer trials units in Europe since 2002 and receives major grants from Cancer Research UK and other charitable organizations. He works extensively with Cancer Research UK and is an Associate Director of the National Cancer Research Network.
He lectures nationally and internationally to clinical and scientific audiences as well as with the public and public bodies. He also represents Europe on the Hepatobiliary Task Force of the United States National Cancer Institute (NCI) and advises several international pharmaceutical companies on clinical trial design and implementation.
Dr. Johnson has published over 290 research papers in scientific journals as well as nearly 200 reviews and book chapters in the fields of hepatobiliary cancer, clinical trials, and biomarkers.
Disclosure: In the past two years, Dr. Johnson has served as a consultant/advisor for Light Sciences Oncology, Bayer, SciMedica, Biocompatibles International, MedImmune, Chugai Pharma, and BMS; has received honoraria from Biocompatibles International and Bayer HealthCare; and has received research funding from Chugai Pharma.
Last Updated: May 24, 2012